Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Sponsored Content: Spinal Muscular Atrophy

Growing evidence for nusinersen in adult patients with 5q SMA.

    • Neurology
    • RX
  • 4 minute read

Until a few years ago, there were only symptomatic treatment options for children and adults with spinal muscular atrophy (SMA). This has changed. New evidence reinforces that nusinersen-treated adult 5q-SMA patients can effectively halt natural disease progression and even gain new motor function. In addition, improvements in bulbar and respiratory functions are also evident, which is particularly important for the quality of life of affected patients.

5q-associated spinal muscular atrophy (5q-SMA) results in progressive loss of motoneurons [1,2]. Treatment with nusinersen can slow down increasing muscle weakness and stabilize or even improve motor skills. Clinically significant therapeutic success can also be seen in adult patients with 5q-SMA type 2 or 3, as experts presented at a Biogen symposium at the virtual 93rd DGN Congress using several observational studies [3,4].

Natural course of the disease

In SMA with later onset (SMA types 2 and 3), there is progressive muscle weakness and loss of motor function in all age groups [1,2]. The progressive muscle weakness and concomitant loss of motor function is evident in the natural history of SMA in routine clinical practice, including the following:

  • HFMSE*: Decrease of HFMSE score by 0.5 – 1.0 points per year[3].
  • RULM**: Decrease of RULM score by 0.41 points per year [5].
  • 6-MWD§: decrease in 6-minute walking distance by 20.8 meters (11-19 years) and 9.7 meters (≥20 years) per year, respectively [6].

Recently, the results of a long-term study (1989-2020) of 104 untreated SMA patients were published, reiterating the continuously decreasing muscle strength by dynamometer measurements [2]. Significant increases in muscle strength have been measured in childhood for both SMA type 2 and SMA type 3. However, after maximum muscle strength was reached, it decreased continuously, indicating that SMA types 2 and 3 are degenerative disease patterns with a delayed-onset disease symptomatology. These results justify the use of currently available therapies in adult SMA patients to stop the continuous loss of muscle strength and improve patients’ independence and quality of life [2].

In another study, patients were also found to have progressive bulbar dysfunction and decreased mouth opening in SMA patients, two parameters that have a particularly high impact on quality of life [7]. In essence, patients primarily describe a desire to maintain skills that contribute to being able to live independently. These include, for example, independent eating, independent personal hygiene, or operating a computer keyboard, skills that enable patients to access the labor market and interact with their social environment [8].

* HFMSE = Hammersmith Functional Motor Scale Expanded
** RULM = Revised Upper Limb Module
§ 6-MWD = 6-minute walking distance
‡ FVC = Forced Vital Capacity

 

Nusinersen in everyday life

The goals of therapy with nusinersen include not only preservation, but also improvement of motor functions in order to preserve the social and financial independence of SMA patients and to enable a positive impact on quality of life. These therapeutic effects of nusinersen were also confirmed in a study of 124 adolescents and adults with 5q-SMA. In this, in addition to stabilization, improvement within several motor function scores was even demonstrated [3].

These findings are reinforced by a 14-month, independent, retrospective cohort study evaluating the efficacy and safety of nusinersen in adults (n = 116; median age 34 years) with genetically confirmed 5q-SMA type 2 or 3 at 18 neurological centers in Italy: on nusinersen, the HFMSE score (median increase) improved by 3 points (p = 0.0014) in sedentary patients and by 2 points (p = 0.00016) in ambulatory patients. In patients with 5q-SMA type 3, a significant improvement in RULM score was observed between study entry and month 14 (+0.5 points [range: -6 to 6]; p = 0.012). Median 6-minute walk distance improved by 20 meters ([range: -101 to 111]; p = 0.016). In the ambulatory patients with 5q-SMA type 3, a significant increase in FVC‡ value was observed after 14 months (+7% [range: +1 to 29]; p = 0.031 [9].

Participants in a recently published study reported overall subjective improvements in terms of greater range of motion in the fingers and hands; louder voice; improved jaw movement and speech, which went against the natural progression of progressive bulbar dysfunction, positively [7].

Brief technical information Spinraza®

Literature

1 Wadman RI, et al: Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2018; 25: 512-518.
2. Crawford TO, et al: Long-term Natural History of Dynamometermeasured Muscle Power in Untreated Spinal Muscular Atrophy Types 2 and 3; MDA (2021) Muscular Dystrophy Association Clinical and Scientific Conference, March 15-18, 2021.
3 Hagenacker T, et al: Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020; 19(4): 317-325.
4 Walter MC, et al: Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study. J Neuromuscul Dis 2019; 6: 453-465.
Pera MC, Coratti G, Mazzone ES, et al: Revised Upper Limb Module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019; 59(4): 426-430.
6. Mazzone E, et al: Six minute walk test in type III spinal muscular atrophy: a 12 month longitudinal study. Neuromuscul Disord 2013; 23: 624-628.
7. Duong, et al: Nusinersen Treatment in Adults with SMA; Neurology Clinical Practice 2021.
8. Rouault F, et al: Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord. 2017; 27: 428-438.
9 Maggi L et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020; 91: 1166 – 1174.
 
Partner
  • biogen
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Previous Article
  • Bullous pemphigoid: case report

Immuno-serological evidence led to the diagnosis

  • Cases
  • Dermatology and venereology
  • Education
  • RX
View Post
Next Article
  • Pemphigus diseases

How this autoimmune dermatosis can be managed nowadays

  • Allergology and clinical immunology
  • Congress Reports
  • Dermatology and venereology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.